Avalon GloboCare Corp. (AVCO) Stock Analysis
DELISTED 2022
What happened to Avalon GloboCare Corp. (AVCO) stock?
Avalon GloboCare Corp. (AVCO) no longer trades on public markets. It was delisted in November 2022. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Avalon GloboCare Corp. (AVCO) trades at $0.5259. Avalon GloboCare Corp. operates in the real estate and medical consulting sectors, with a focus on developing innovative cell therapies and exosome technology. Market cap: $5.26M, Sector: Real estate.
Last analyzed: May 10, 2026Analyst Coverage for AVCO: AVCO does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates AVCO against Real Estate peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
AVCO: 1/2 scored disciplines lean bearish. Dominant signal: Izzy Englander bullish.
How is this calculated? →Avalon GloboCare Corp. (AVCO) Real Estate Portfolio & Strategy
Avalon GloboCare Corp. operates in the real estate and medical consulting sectors, focusing on commercial real estate ownership and medical-related consulting services. The company is also involved in developing innovative cell therapies, including CAR-T cell therapies and exosome technology, positioning it at the intersection of real estate and biotechnology.
What Is the Investment Thesis for AVCO?
Avalon GloboCare presents a speculative investment opportunity due to its diverse business model, combining real estate with early-stage biotechnology development. Key value drivers include the potential success of its CAR-T cell therapy candidates, AVA-001 and AVA-011, and its innovative exosome technology. The company's strategic partnerships, such as the one with MIT for QTY-code protein design and the University of Natural Resources and Life Sciences for vaccine development, could provide significant growth catalysts. However, the company's small market capitalization of $5.26M and limited number of employees (5) indicate high risk. The success of its therapeutic programs is contingent on positive clinical trial outcomes and regulatory approvals, which are subject to uncertainty. The real estate component provides some stability, but the overall investment is heavily weighted towards the success of its biotechnology ventures. Investors should carefully consider the high-risk, high-reward nature of this investment.
Based on FMP financials and quantitative analysis
AVCO Key Highlights
Market capitalization of $5.26M, indicating a micro-cap company with high growth potential but also significant risk.
- Development of AVA-001, an anti-CD19 CAR-T therapy that has completed first-in-human clinical trial for relapsed/refractory B-cell lymphoblastic leukemia.
- Strategic partnership with MIT to develop therapeutic and diagnostic targets utilizing QTY-code protein design technology.
- Collaboration with the University of Natural Resources and Life Sciences in Vienna, Austria, to develop an S-layer vaccine against SARS-CoV-2 and other coronaviruses.
- Beta of 0.81, suggesting lower volatility compared to the overall market.
Who Are AVCO's Competitors?
AVCO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ZDPY Zoned Properties, Inc. | $0.42 | -9.91% | $5.57M | 58 |
| HWTR HFactor, Inc. | $0.23 | +0.00% | $11.6M | 62 |
| BCKMF The Becker Milk Company Limited | $9.80 | +0.00% | $17.7M | 52 |
| LGPS LogProstyle Inc. | $0.87 | +0.44% | $20.5M | 51 |
| ASPZ Asia Properties, Inc. | $0.04 | +0.00% | $25.9M | 51 |
| WE WeWork Inc. | $0.84 | -24.73% | $44.1M | 51 |
| PCPDF Pacific Century Premium Developments Limited | $0.03 | +0.00% | $65.4M | 56 |
| CRSS Crossroads Impact Corp. | $7.00 | +0.00% | $74.3M | 66 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are AVCO's Key Strengths?
Innovative CAR-T cell therapy pipeline.
- Strategic partnerships with MIT and the University of Natural Resources and Life Sciences.
- Proprietary exosome technology platform (ACTEX).
- Diversified business model with real estate and medical consulting services.
What Are AVCO's Weaknesses?
Small market capitalization and limited number of employees.
- Early-stage development of therapeutic candidates with high clinical trial risk.
- Dependence on external funding and partnerships.
- Limited commercialization experience.
What Could Drive AVCO Stock Higher?
Clinical trial results for AVA-001 CAR-T cell therapy in relapsed/refractory B-cell lymphoblastic leukemia.
- IND submission and initiation of clinical trials for AVA-011 CAR-T cell therapy.
- Progress in the development of the S-layer vaccine against SARS-CoV-2 and other coronaviruses.
- Expansion of medical consulting services and revenue generation.
- Advancement of the ACTEX exosome technology platform.
What Are the Key Risks for AVCO?
Financial-distress signal — its Altman Z-Score of -12.64 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Failure to obtain regulatory approvals for CAR-T cell therapies and other therapeutic candidates.
- Unsuccessful clinical trial outcomes.
- Competition from larger, more established biotechnology companies.
- Dependence on external funding and partnerships.
- Economic downturn affecting real estate property values.
What Are the Growth Opportunities for AVCO?
- Development and Commercialization of CAR-T Cell Therapies: Avalon GloboCare's lead candidates, AVA-001 and AVA-011, represent significant growth opportunities in the CAR-T cell therapy market. Successful completion of clinical trials and regulatory approval could lead to substantial revenue generation. The company's focus on relapsed/refractory B-cell lymphoblastic leukemia positions it in a niche market with unmet medical needs. Timeline: Ongoing clinical trials with potential commercialization within 3-5 years.
- Exosome Technology Platform (ACTEX): The development of Avalon clinical-grade tissue-specific exosomes (ACTEX) offers potential applications in diagnostics and therapeutics. The exosome market is rapidly expanding, driven by increasing research and development activities. Avalon GloboCare's ACTEX platform could be used for targeted drug delivery and regenerative medicine. Timeline: Pre-clinical development with potential for clinical trials in 2-3 years.
- QTY-Code Protein Design Technology: Avalon GloboCare's collaboration with MIT to utilize QTY-code protein design technology for therapeutic and diagnostic targets represents a significant growth opportunity. This technology could lead to the development of novel therapies for various diseases, including cytokine storm. Timeline: Ongoing research and development with potential for clinical applications in 3-5 years.
- S-Layer Vaccine Development: The strategic partnership with the University of Natural Resources and Life Sciences in Vienna to develop an S-layer vaccine against SARS-CoV-2 and other coronaviruses offers a potential growth opportunity in the vaccine market. The ability to administer the vaccine intranasally or orally could provide a competitive advantage. Timeline: Ongoing research and development with potential for clinical trials in 1-2 years.
- Expansion of Medical Consulting Services: Avalon GloboCare's medical consulting services, including research studies, executive education, and expert advisory services, provide a stable revenue stream and opportunities for growth. The increasing demand for specialized medical expertise and consulting services supports the expansion of this business segment. Timeline: Ongoing with continuous growth potential.
What Are AVCO's Competitive Advantages?
- Proprietary CAR-T cell therapy technology (AVA-001 and AVA-011).
- Exclusive rights to QTY-code protein design technology through collaboration with MIT.
- Strategic partnerships with leading research institutions and universities.
- Early-stage development of innovative exosome technology (ACTEX).
What Does AVCO Do?
Avalon GloboCare Corp., along with its subsidiaries, is involved in owning and operating commercial real estate properties in both the United States and the People's Republic of China. Founded with a vision to integrate real estate holdings with advanced medical technologies, the company has evolved to offer a range of medical-related consulting services. These services include research studies, executive education, daily online executive briefings, tailored expert advisory services, and consulting and management services, specifically in the areas of immunotherapy and second opinion/referral services. Avalon GloboCare's leading therapeutic candidates include AVA-001, an anti-CD19 CAR-T therapy that has completed a first-in-human clinical trial for relapsed/refractory B-cell lymphoblastic leukemia, and AVA-011, which is undergoing pre-clinical laboratory studies and IND-enabling process development to generate cGMP-grade AVA-011 CAR-T cells. The company is also developing an RNA-based FASH-CARTM cell therapy platform. Furthermore, Avalon GloboCare develops Avalon clinical-grade tissue-specific exosomes (ACTEX) and offers therapeutic and diagnostic targets utilizing QTY-code protein design technology in collaboration with the Massachusetts Institute of Technology (MIT). This technology is being used for the development of a hemofiltration device designed to treat Cytokine Storm. The company also engages in the co-development of next-generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare has a strategic partnership with the University of Natural Resources and Life Sciences in Vienna, Austria, to develop an S-layer vaccine that can be administered intranasally or orally against SARS-CoV-2 and other coronaviruses. The company is also developing Avalon Cell and Avalon Rehab, and promotes standardization within the exosome industry. Headquartered in Freehold, New Jersey, Avalon GloboCare operates both domestically and internationally.
What Products and Services Does AVCO Offer?
- Owns and operates commercial real estate properties in the United States and China.
- Offers medical-related consulting services, including research studies and executive education.
- Develops AVA-001, an anti-CD19 CAR-T therapy for relapsed/refractory B-cell lymphoblastic leukemia.
- Develops AVA-011 CAR-T cells, currently in pre-clinical studies.
- Develops an RNA-based FASH-CARTM cell therapy platform.
- Develops Avalon clinical-grade tissue-specific exosomes (ACTEX).
- Offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with MIT.
- Develops an S-layer vaccine against SARS-CoV-2 and other coronaviruses in partnership with the University of Natural Resources and Life Sciences in Vienna.
How Does AVCO Make Money?
- Generates revenue from commercial real estate property ownership and operations.
- Provides medical-related consulting services for fees.
- Seeks to generate revenue through the development and commercialization of CAR-T cell therapies.
- Aims to monetize its exosome technology platform through licensing and partnerships.
- Pursues revenue through collaborative research and development agreements.
What Industry Does AVCO Operate In?
Avalon GloboCare operates at the intersection of the real estate and biotechnology industries. The real estate services sector is characterized by cyclical trends influenced by economic conditions and interest rates. The biotechnology industry is experiencing rapid growth, driven by advancements in cell therapy, exosome technology, and vaccine development. Avalon GloboCare's positioning allows it to potentially capitalize on both sectors, although it also faces challenges related to regulatory hurdles, clinical trial risks, and competition from larger, more established biotechnology companies. The company's focus on innovative therapies aligns with the broader industry trend towards personalized medicine and targeted treatments.
Who Are AVCO's Key Customers?
- Tenants of its commercial real estate properties.
- Healthcare organizations and professionals seeking medical consulting services.
- Patients with relapsed/refractory B-cell lymphoblastic leukemia (potential future customers).
- Pharmaceutical companies interested in licensing or partnering for its CAR-T cell therapies and exosome technology.
- Research institutions and universities collaborating on research and development projects.
How Avalon GloboCare Corp. Is Valued
Avalon GloboCare Corp. carries a market capitalization of $5.26M, placing it in the micro-cap category.
Company Profile
Avalon GloboCare Corp. operates in the Real Estate - Services industry within the Real Estate sector. It is headquartered in Freehold, US. The company is led by CEO David K. Jin. AVCO has traded publicly since 2016.
Financial Health
Avalon GloboCare Corp.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.64 places it in the distress zone, a signal of elevated financial risk.
AVCO Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Avalon GloboCare's recent insider buying suggests confidence from within, a positive signal often interpreted as belief in future growth.
- The community sentiment appears to be leaning bullish, with many traders expressing optimism about the company's strategic direction.
- Market perception seems to be improving, with increased attention and discussion around Avalon GloboCare's potential in its specific sector.
- The company's recent announcements regarding partnerships and expansions are being viewed favorably, potentially driving long-term value.
Bear Case
- Some community members express concerns about Avalon GloboCare's ability to scale effectively, citing past performance challenges.
- There's a perception that the market may be overvaluing the company's future prospects based on current achievements.
- Recent insider selling, while not as prevalent as buying, raises questions among some investors about potential short-term headwinds.
- Despite positive announcements, skepticism remains regarding the actual impact of these developments on Avalon GloboCare's bottom line.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
AVCO Latest News
No recent news available for AVCO.
Leadership: David K. Jin
CEO
David K. Jin serves as the CEO of Avalon GloboCare Corp. His background includes experience in managing and overseeing the company's diverse operations, including real estate holdings and biotechnology development. He is responsible for guiding the company's strategic direction and fostering partnerships with leading research institutions. His leadership is focused on advancing Avalon GloboCare's pipeline of CAR-T cell therapies and exosome technology.
Track Record: Under David K. Jin's leadership, Avalon GloboCare has advanced its CAR-T cell therapy candidate, AVA-001, through a first-in-human clinical trial. He has also spearheaded strategic partnerships with MIT and the University of Natural Resources and Life Sciences. His tenure has focused on driving innovation and expanding the company's presence in the biotechnology sector. He manages a small team of 5 employees.
Avalon GloboCare Corp. Real Estate Stock: Key Questions Answered
What happened to Avalon GloboCare Corp. (AVCO) stock?
Avalon GloboCare Corp. (AVCO) no longer trades on public markets. It was delisted in November 2022. The figures below are historical and are not a current quote.
Can I still buy AVCO shares?
No. AVCO stopped trading on public markets in November 2022, so the shares are not available through a broker. Anything you see quoted for AVCO elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before AVCO stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Avalon GloboCare Corp.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Avalon GloboCare Corp. do?
Avalon GloboCare Corp. operates in the real estate and medical sectors. It owns and operates commercial real estate properties in the U.S. and China, and provides medical-related consulting services. The company is also developing innovative cell therapies, including AVA-001, an anti-CD19 CAR-T therapy, and AVA-011, currently in pre-clinical studies.
What do analysts say about AVCO stock?
Given Avalon GloboCare's small market capitalization of $5.26M, limited analyst coverage is expected. Any analyst reports should be viewed with caution, considering the company's early-stage development and high-risk profile. Key valuation metrics would likely focus on the potential of its CAR-T cell therapy pipeline and exosome technology.
What are the main risks for AVCO?
Avalon GloboCare faces significant risks associated with its early-stage biotechnology development. These include the potential failure to obtain regulatory approvals for its CAR-T cell therapies and other therapeutic candidates, as well as the risk of unsuccessful clinical trial outcomes. Competition from larger, more established biotechnology companies also poses a threat.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- The company's future performance is subject to various risks and uncertainties.
- This is not investment advice. Conduct thorough research before making any investment decisions.